Cancer
Select a country to see country specific content
Oncology is the study of cancer, dedicated to its investigation, diagnosis, and treatment.[1] Oncologists focus on the diagnosis and treatment of cancer, and also contribute to cancer research.[1] Commonly, three types of oncologists are distinguished: medical, surgical and radiation.[1]
Oncology is one of Janssen's areas of expertise. Our goal is to make cancer not only manageable but also, one day, curable, by developing transformational and targeted treatment solutions that improve lives and enable those affected by cancer to enjoy more of life’s meaningful moments.
At Janssen, we focus on cancer subtypes we know best, so that our deep expertise and experience can create the highest impact in terms of finding a cure and transforming the lives of people with cancer for the better.
Our best chance of achieving this focused, long-term commitment is with the help of ground-breaking technological advances and carefully selected partners across the globe.
Through our discovery, development and collaboration efforts, we continue to advance a comprehensive, differentiated portfolio and pipeline of small molecules, biologics and cell therapies for patients with haematological malignancies, prostate cancer, lung cancer and bladder cancer.
Explore our Disease Areas
Bladder cancer is a common form of cancer. Nearly 550,000 new cases were diagnosed in 2018 and men are four times more likely to be affected than women.[2] Bladder cancer occurs when the cells that make up the urinary bladder begin to grow uncontrollably. [3] The most common form of bladder cancer is urothelial carcinoma, also known as transitional cell carcinoma (TCC), which starts from the urothelial cells that line the inside of the bladder.[3] Other forms of bladder cancer can develop elsewhere in the urinary tract, but these are all much less common.[3]
Prostate cancer is a type of cancer that develops in the prostate gland, located just behind the bladder.[6] Each year, approximately 450,000 people in Europe are diagnosed with the condition, and it is now the second commonest cause of male cancer death.[7] Most people with early-stage prostate cancer are asymptomatic.[8] Screening for prostate cancer can play an important role in improving men's understanding of their health as part of an informed decision-making process with health care professionals.[7]
References
